Project Grant K99NS144514
- This $2,503,949 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at Rockefeller University aimed at discovering therapeutic targets for neurological diseases. The project utilizes new techniques and concepts to study the fundamental mechanisms of brain disorders, focusing on how differences in cell-specific RNA regulation contribute to...
- This Project Grant award of $460,625 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research to investigate the roles of the deubiquitylation pathway in TDP-43 pathology associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The research is being conducted by the University of Massachusetts Medical School (UMMS) and...
- This $147,486 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to understand the disease mechanism and develop gene therapy for a common and understudied STXBP1 missense variant that causes severe developmental and epileptic encephalopathy. The applicant has established a mouse model that recapitulates key neurological symptoms of this...
- This federal Project Grant award, funded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, consolidates multiple research projects into a single larger R35 grant to enable comprehensive exploration of biological mechanisms underlying neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Parkinson's disease. The...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $1,138,538 to Mayo Clinic Jacksonville to expand research into the mechanisms underlying frontotemporal lobar degeneration (FTLD), which causes frontotemporal dementia (FTD) and is genetically linked to amyotrophic lateral sclerosis (ALS). The research aims to investigate key...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) provides $653,192 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a longitudinal study on non-invasive imaging of pathological fibrin deposition and its effects on progressive neurodegeneration in the human brain. The research aims to investigate whether and to...
- This Project Grant award for $470,786, issued on May 15, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to investigate the relationship between aging, immune function, and mitochondrial dysfunction in the pathogenesis of vascular cognitive impairment...
- This federal Project Grant award of $228,555 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research on the role of the STRADA gene in inhibitory neuron migration and cortical development. The research aims to understand how loss of the STRADA gene, which causes a severe neurological condition called PMSE, leads to impaired migration of inhibitory...
- This $3,081,936 federal Project Grant award was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The award supports research at the University of California, San Diego (UCSD) to investigate the mechanisms underlying TDP-43 proteinopathies, which are associated with amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease,...
- This Project Grant award of $426,313, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), supports research at The Johns Hopkins University to investigate the signaling pathways that disrupt neurofilament (NF) phosphorylation dynamics and lead to NF hyperphosphorylation, a pathology associated with neurodegenerative diseases such as amyotrophic lateral...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $129,170 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to elucidate the toxic mechanisms underlying the somatic expansion of short tandem repeats (STRs) in repeat expansion diseases (REDs). The project aims to identify the STR length needed to trigger toxicity in vulnerable brain cells and investigate whether methylation modulates somatic expansion of the STR, using genomics, transcriptomics, and cell-based strategies. This research focuses on X-linked dystonia parkinsonism (XDP), a neurological disorder, and will later expand to study more complex REDs, such as those associated with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The award period runs from August 1, 2025, to July 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $129.2k | 7/25/25 |